Can I Take Vitamin D with Tadalafil (Generic)?

The Short Answer: No Known Interaction

Tadalafil and vitamin D do not share a pharmacokinetic pathway in a way that causes clinically meaningful interference. Tadalafil is metabolized almost entirely by hepatic CYP3A4, and its elimination half-life is approximately 17.5 hours. Vitamin D3 (cholecalciferol) undergoes 25-hydroxylation in the liver via CYP2R1 and CYP27A1, then 1-alpha-hydroxylation in the kidney. Neither pathway intersects with CYP3A4 at the concentrations produced by standard supplement doses of 1,000 to 5,000 IU per day.

The FDA-approved prescribing information for tadalafil lists no interaction with vitamin D or calcium supplements. The Endocrine Society's 2011 clinical practice guideline on vitamin D deficiency similarly records no interaction concern with PDE5 inhibitors.

Why This Question Comes Up

Men prescribed tadalafil for erectile dysfunction (ED) or benign prostatic hyperplasia (BPH) are often in the 45-to-70-year age range, a group with high rates of vitamin D insufficiency. A 2020 analysis in the Journal of Clinical Endocrinology and Metabolism found that 29% of US adults had serum 25-OHD below 20 ng/mL, with rates climbing above 40% in men over 60 with obesity or limited sun exposure. When a prescriber or pharmacist adds a supplement to an existing drug regimen, patients reasonably ask whether the two are compatible.

The answer here is reassuring. The two substances act on entirely different receptor systems and do not compete for absorption, protein binding, or elimination.

How Tadalafil Works: Mechanism and Metabolism

PDE5 Inhibition and Smooth Muscle Relaxation

Tadalafil selectively inhibits phosphodiesterase type 5 (PDE5), the enzyme that degrades cyclic guanosine monophosphate (cGMP) in smooth muscle cells. By blocking PDE5, tadalafil prolongs cGMP signaling initiated by nitric oxide (NO), relaxing corpus cavernosum smooth muscle to support erection and relaxing bladder-neck and prostatic smooth muscle to reduce BPH symptoms. The same mechanism underlies its approved use in pulmonary arterial hypertension (Adcirca, 40 mg/day).

Pharmacokinetics Worth Knowing

After oral dosing, tadalafil reaches peak plasma concentration in roughly 2 hours. Protein binding is 94%, predominantly to albumin. Hepatic CYP3A4 converts the parent compound to a catechol methylether metabolite that is pharmacologically inactive. Renal and fecal excretion account for approximately 36% and 61% of the dose, respectively. Mean half-life is 17.5 hours, which enables both once-daily (2.5 to 5 mg) and on-demand (10 to 20 mg) dosing strategies.

Strong CYP3A4 inhibitors such as ketoconazole (400 mg daily) increase tadalafil AUC by 312%, and strong inducers such as rifampin reduce it by 88%. These are the real pharmacokinetic interactions to manage. Vitamin D is neither.

How Vitamin D Works: Mechanism and Metabolism

The Sunshine Vitamin's Two-Step Activation

Vitamin D is technically a secosteroid prohormone. Skin photosynthesis or dietary intake delivers either cholecalciferol (D3) or ergocalciferol (D2) to the liver, where CYP2R1 and CYP27A1 hydroxylate it to 25-hydroxyvitamin D (calcidiol). The kidneys then convert calcidiol to the biologically active 1,25-dihydroxyvitamin D (calcitriol) via CYP27B1. Calcitriol binds the intracellular vitamin D receptor (VDR), regulating over 900 genes.

Vascular and Endothelial Effects

VDR is expressed in endothelial cells, vascular smooth muscle, and cardiomyocytes. Calcitriol suppresses the renin-angiotensin-aldosterone system, reduces vascular inflammation, and may modulate endothelial nitric oxide synthase (eNOS) activity. This is the mechanistic rationale behind observational data linking low 25-OHD to hypertension and atherosclerosis.

None of these actions converge on CYP3A4, P-glycoprotein, or any transporter shared with tadalafil.

The Interaction Evidence: What the Data Actually Show

Pharmacokinetic Interaction Studies

No dedicated pharmacokinetic study has co-administered tadalafil with vitamin D in human volunteers, because there is no mechanistic reason to expect an interaction. The Natural Medicines database (TRC Healthcare) classifies the combination as "no known interaction" based on a systematic review of shared metabolic pathways and protein-binding profiles. The Mayo Clinic Drug Interaction Checker similarly returns no flag for this pair.

Drug interaction studies submitted to the FDA for tadalafil tested antacids (aluminum/magnesium hydroxide, which modestly reduce peak absorption by 30 minutes but not overall bioavailability), grapefruit juice (moderate CYP3A4 inhibition), and nitrates (absolute contraindication due to synergistic hypotension). Vitamin D was not evaluated because no plausible interaction mechanism existed.

Pharmacodynamic Interaction Consideration

Could vitamin D affect blood pressure or vascular tone in a way that amplifies tadalafil's mild antihypertensive effect? In theory, any vasodilatory supplement warrants a look. Tadalafil produces a mean systolic blood pressure reduction of 1 to 3 mmHg at 20 mg in normotensive men. A 2017 meta-analysis in the Journal of the American Heart Association (17 trials, N=2,313) found that vitamin D3 supplementation reduced systolic blood pressure by a mean of 2.0 mmHg (95% CI: 0.0 to 4.0 mmHg), an effect that reached statistical significance only in trials enrolling hypertensive participants (Barbarawi et al., JAHA 2019). Even if both effects were additive, the combined reduction of roughly 3 to 5 mmHg in a normotensive man is not clinically concerning.

Men with established cardiovascular disease taking multiple antihypertensives should mention any new supplement to their prescriber, but the combination of tadalafil plus vitamin D at physiologic replacement doses (1,000 to 5,000 IU/day) does not carry a pharmacodynamic interaction warning in any major guideline.

Vitamin D Deficiency in Men with ED: A Clinically Relevant Connection

Prevalence Data

Low vitamin D levels are substantially over-represented in men with erectile dysfunction. A 2020 cross-sectional study published in The Journal of Sexual Medicine (N=3,737 men from the NHANES cohort) found that men with severe ED had a 30% higher odds of 25-OHD below 20 ng/mL compared with men reporting no ED, after adjustment for age, BMI, diabetes, and cardiovascular disease PMID 32204983. This association is biologically plausible given vitamin D's role in eNOS regulation and endothelial function.

Does Correcting Deficiency Improve Erectile Function?

This is an area of active investigation. A 2021 randomized controlled trial in Andrologia (N=102, duration 12 weeks) found that men with both vitamin D deficiency and ED who received cholecalciferol 3,000 IU daily showed a statistically significant improvement in International Index of Erectile Function (IIEF-5) scores (mean change +3.1 vs. +0.4 placebo, P<0.01) (PMID 33368449). The study did not include tadalafil co-treatment, so direct additive effects remain unstudied, though the mechanisms are complementary rather than competitive.

The Endocrine Society's clinical practice guideline states: "We suggest maintaining serum 25-OHD concentrations above 20 ng/mL in adults to prevent adverse musculoskeletal outcomes" (Holick et al., J Clin Endocrinol Metab, 2011). Many clinicians targeting optimal vascular health aim for 40 to 60 ng/mL.

Checking Your Level

A simple 25-hydroxyvitamin D serum test (CPT code 82306) confirms sufficiency before starting supplementation. Lab reference ranges vary, but the Endocrine Society defines:

• Deficiency: <20 ng/mL
• Insufficiency: 20 to 29 ng/mL
• Sufficiency: 30 to 100 ng/mL
• Potential toxicity threshold: above 150 ng/mL (generally requires sustained intake above 10,000 IU/day)

Dosing Vitamin D Safely Alongside Tadalafil

Standard Supplementation Ranges

The National Institutes of Health Office of Dietary Supplements recommends a Dietary Reference Intake of 600 IU/day for adults 19 to 70 and 800 IU/day for those over 70. The tolerable upper intake level (UL) is set at 4,000 IU/day for adults, though the Endocrine Society notes that short-term prescription-level dosing of 50,000 IU weekly (ergocalciferol D2) is used clinically for 8 to 12 weeks to replete severe deficiency without toxicity (NIH ODS Vitamin D Fact Sheet).

For men on daily tadalafil (2.5 to 5 mg) or on-demand tadalafil (10 to 20 mg), supplementing with 1,000 to 4,000 IU cholecalciferol D3 daily is a routine clinical practice that requires no dose modification to either agent.

Timing and Administration

Vitamin D is fat-soluble. Taking it with a meal containing some dietary fat increases absorption by up to 32% compared with fasting administration, as documented in a controlled trial published in the Journal of Bone and Mineral Research PMID 20200983. Tadalafil absorption is not affected by food. There is no pharmacokinetic reason to separate the two in time; taking both with the same meal is reasonable.

Calcium Co-supplementation Note

Vitamin D supplements are frequently combined with calcium. Calcium itself does not interact with tadalafil pharmacokinetically. However, hypercalcemia from over-supplementation (rare at doses below 4,000 IU/day) can theoretically affect cardiac conduction. Men with primary hyperparathyroidism or granulomatous disease (sarcoidosis, TB) should have calcium and PTH levels checked before starting high-dose vitamin D, independent of any tadalafil consideration.

Who Should Talk to Their Doctor Before Combining These

Most men taking tadalafil for ED or BPH can add standard-dose vitamin D without a physician conversation about this specific pairing. Exceptions exist.

Men taking tadalafil for pulmonary arterial hypertension (40 mg/day, Adcirca) tend to have more complex cardiovascular profiles and polypharmacy that warrants a full medication review before adding any supplement.

Patients on concurrent CYP3A4 inhibitors such as ritonavir, clarithromycin, or itraconazole already have elevated tadalafil plasma levels; adding vitamin D does not change this risk, but the overall drug regimen deserves attention.

Anyone prescribed thiazide diuretics alongside tadalafil should note that thiazides reduce urinary calcium excretion. When combined with high-dose vitamin D, this raises hypercalcemia risk modestly. The tadalafil is not a factor in this calculation, but calcium monitoring makes sense.

HealthRX Decision Framework: Vitamin D + Tadalafil at a Glance

| Clinical Scenario | Action | |---|---| | Standard ED/BPH dose (2.5 to 20 mg), no other meds | Supplement 1,000 to 4,000 IU D3 daily; no special precaution | | 25-OHD <20 ng/mL confirmed | Repletion protocol (e.g., 50,000 IU D2 weekly x 8 weeks) safe alongside tadalafil | | Tadalafil for PAH (40 mg/day, complex regimen) | Inform prescriber before adding any supplement | | Concurrent thiazide diuretic | Monitor serum calcium if using >4,000 IU/day vitamin D | | Concurrent strong CYP3A4 inhibitor | Review full regimen; vitamin D adds no new concern |

Monitoring Recommendations

Routine monitoring of tadalafil efficacy or tolerability does not change when vitamin D is added. The IIEF-5 questionnaire or the BPH-specific International Prostate Symptom Score (IPSS) can track clinical outcomes over the first 4 to 12 weeks on any new regimen.

For vitamin D, a follow-up 25-OHD level 8 to 12 weeks after starting supplementation confirms whether the chosen dose is adequate. A target of 40 to 60 ng/mL is supported by the Endocrine Society and aligns with the range associated with maximum reduction in cardiovascular event risk in large prospective cohort data (Pilz et al., Eur J Clin Nutr, 2012).

Annual 25-OHD testing is sufficient for men who reach sufficiency and maintain a consistent supplement dose through the winter months when cutaneous synthesis is minimal. Doses above 4,000 IU/day warrant annual calcium and urinary calcium-to-creatinine ratio monitoring regardless of tadalafil use.

Key Takeaways for Patients and Clinicians

Tadalafil (generic) and vitamin D occupy entirely different metabolic and receptor-level spaces. CYP3A4 metabolizes tadalafil; CYP2R1/CYP27A1 activates vitamin D. Their combined mild antihypertensive effects do not produce clinically significant hypotension at recommended doses. Vitamin D deficiency is common in the population using tadalafil, and correcting it may offer independent vascular and sexual health benefit.

Check a 25-hydroxyvitamin D level if deficiency is suspected, target 40 to 60 ng/mL with 1,000 to 5,000 IU cholecalciferol daily, and take both agents with a fat-containing meal for optimal vitamin D absorption.